辛伐他汀治疗急性冠脉综合征的疗效观察  

Evaluation of Simvastatin in the Treatment of Acute Coronary Syndrome

作　　者：谢晓明[1] 廖华[2] 

机构地区：[1]广东医学院附属医院,广东湛江524001 [2]广东省湛江中心人民医院,广东湛江524037

出　　处：《河北医学》2005年第9期794-796,共3页Hebei Medicine

摘　　要：目的:研究急性冠脉综合征(ACS)早期应用辛伐他汀对血脂、缺血事件发生的影响。方法:60例ACS患者被随机分为对照组(n=30)和治疗组(n=30,用辛伐他汀治疗)观察用药前后血脂、缺血事件发生情况。结果:对照组治疗前后血脂无显著变化(P>0.05)。与对照组相比,治疗组用药后血脂明显下降(P<0.05),缺血事件发生率明显下降(X2=4.72,P<0.05)。两组治疗前、后肝、肾功能,肌酸磷酸激酶水平均无明显变化。结论:ACS早期应用辛伐他汀可明显降低缺血事件发生率。Objective: To observe the influence of early simvastatin treatment on serum lipids and ischemic events in patients with acute coronary syndrome(ACS).Method: Sixty patients with ACS were divided into control group(n30) and therapy group(n30) randomizely, and the changes of serum lipeid and the incidence of ischemic events were observed.Result: After treatment of simvastatin, the levels of serum lipids and incidence of ischemic events significantly decreased compared with those of control groups (all p<0.05). Before and after treatment, the levels of serum lipids in control group, renal function, Liver function and creatine phosphokinase in both two groups had no change. Conclusion: Early simvastatin treatment could significantly reduce incidence of ischemic events in patients of ACS.

关 键 词：急性冠脉综合征 辛伐他汀 缺血事件 

分 类 号：R541.4[医药卫生—心血管疾病]